Join Xconomy as we bring together a conference of Boston biotech’s top entrepreneurs, experts, investors, and leaders to network and explore these and other innovations on the life science horizon. Featuring networking opportunities and speakers from the Broad Institute, Novartis, Moderna, Lyndra, and more.
In many ways, 2017 marked a turning point for biomedical innovation. Just look at the news: The FDA approved the first U.S. gene therapy, the first CAR-T cellular immunotherapy, the first cancer drug based on a genetic signature, and the first smartphone app to treat substance abuse. Add to that the first successful Phase 3 trial for an RNA interference drug, and 2017 was a year in which medicine began to change significantly.
Yet with those changes come significant questions. How will the U.S. healthcare system handle these newer, longer-lasting treatments? Will there finally be a drug price reckoning as new therapies push costs higher—and will biopharma adapt with innovative payment models? Elsewhere, will setbacks emerge as CRISPR-Cas9 gene editing speeds towards human testing? Will combination treatments expand the reach of cancer immunotherapy, or pose new obstacles? What other trends and developments can we look forward to, and what's the latest in Boston life sciences? Join us at this exclusive biotechnology networking event to find out.
Enter StartHub120 for $120 off regular-priced tickets!